Imazano Y, Takebayashi Y, Nishiyama K, Akiba S, Miyadera K, Yamada Y, Akiyama S, Ohi Y
Department of Cancer Chemotherapy, Institute for Cancer Research, Kagoshima University, Japan.
J Clin Oncol. 1997 Jul;15(7):2570-8. doi: 10.1200/JCO.1997.15.7.2570.
Thymidine phosphorylase (TP) is identical to platelet-derived endothelial cell growth factor (PD-ECGF) and has angiogenic activity. We examined whether TP expression in renal cell carcinoma (RCC) is associated with microvessel density as a marker of angiogenesis, clinicopathologic characteristics, and outcome.
The enzymatic activity and expression of TP were examined in 18 RCCs and 19 kidney tissues not grossly involved with tumor from 24 patients with 13 paired samples and 11 unpaired samples by spectrophotometry and immunoblotting. The relationship between TP expression and microvessel density was assessed by immunohistochemistry in 133 RCCs.
The median enzymatic activity of TP in RCCs was nine fold higher than that in nonneoplastic kidney tissues (P < .001). Similar results were obtained by immunoblot analysis. According to the TP staining profile, tumors were classified as no or low, intermediate, or high TP-expressing tumors. TP positivity was significantly correlated with microvessel density. TP expression was correlated with tumor grade, but there was no significant association between TP expression and other clinicopathologic characteristics. TP expression as a prognostic variable was studied using Cox's proportional hazards model. TP overexpression was an independent prognostic factor (hazards ratio, 3.95; 95% confidence interval, 0.98 to 15.89; P = .039) as were nodal category, metastases category, tumor grade, and venous invasion.
These findings suggest that TP expression is correlated with microvessel density in RCC and is an unfavorable independent prognostic factor. The future development and characterization of TP inhibitors may provide a novel approach to the therapy of RCC.
胸苷磷酸化酶(TP)与血小板衍生内皮细胞生长因子(PD - ECGF)相同,具有血管生成活性。我们研究了肾细胞癌(RCC)中TP的表达是否与作为血管生成标志物的微血管密度、临床病理特征及预后相关。
通过分光光度法和免疫印迹法,对24例患者的18例肾细胞癌及19例未受肿瘤累及的肾组织(其中13对配对样本和11个非配对样本)进行TP的酶活性和表达检测。通过免疫组化法评估133例肾细胞癌中TP表达与微血管密度的关系。
肾细胞癌中TP的中位酶活性比非肿瘤性肾组织高9倍(P <.001)。免疫印迹分析也得到了类似结果。根据TP染色情况,肿瘤被分为无或低、中等或高TP表达肿瘤。TP阳性与微血管密度显著相关。TP表达与肿瘤分级相关,但TP表达与其他临床病理特征之间无显著关联。使用Cox比例风险模型研究TP表达作为预后变量的情况。TP过表达是一个独立的预后因素(风险比,3.95;95%置信区间,0.98至15.89;P =.039),淋巴结分类、转移分类、肿瘤分级和静脉侵犯也是独立预后因素。
这些发现表明,TP表达与肾细胞癌中的微血管密度相关,是一个不良的独立预后因素。TP抑制剂的未来研发和特性研究可能为肾细胞癌的治疗提供一种新方法。